Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer.
Yi
Chunling
C
Molecular and Cellular Oncogenesis Program, The Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104, USA.
Maksimoska
Jasna
J
Marmorstein
Ronen
R
Kissil
Joseph L
JL
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D054462:p21-Activated Kinases / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C515903:PAK1 protein, human; D054462:p21-Activated Kinases